Navigation Links
Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
Date:12/11/2012

n spread to other tissues, such as bone marrow and liver. In the United States, there are approximately 70,130 new cases of NHL and 4,600 new cases of MCL each year.

About Ibrutinib

Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulating B-cell apoptosis, cell adhesion, and lymphocyte migration and homing. Through these multiple actions, BTK helps to direct malignant B cells to lymphoid tissues, thus allowing access to a microenvironment necessary for survival.

The effectiveness of ibrutinib alone or in combination with other treatments is being studied in several B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma, relapsed/refractory mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma and multiple myeloma. The clinical development program includes 23 clinical trials – six Phase 3, nine Phase 2, one Phase 1/2, and seven Phase 1 trials currently underway.

About the Janssen and Pharmacyclics Collaboration

Janssen Biotech, Inc. and Pharmacyclics Inc. entered into a worldwide collaboration on December 8, 2011, to develop and commercialize ibrutinib. Following regulatory approval, Janssen and Pharmacyclics will co-commercialize ibrutinib. In the United States, both companies will share in commercialization activities; outside the United States, Janssen will lead and perform commercialization activities. Each company is leading development for specific indications.

About Janssen Research & Development, LLC

Janssen Research & Development, LLC is headquartered in Raritan, N.J. and has affiliated facilities in Europe, the United States and Asia. Janssen Research & Development is leveraging a combination of internal and external innovation to discover and develop novel
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
2. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
3. Landauer, Inc. Reports Fiscal 2012 Fourth Quarter And Year End Results
4. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
5. IRIDEX Corporation Announces Preliminary Results of its Tender Offer
6. American Pacific to Release Financial Results and Hold Fiscal 2012 Year-End and Fourth Quarter Investor Teleconference
7. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
8. The Female Health Company Reports Record Fourth Quarter and FY2012 Operating Results
9. ObeTherapy Announces the Publication of Results Obtained with one of its Lead Compounds on a New Target for the Treatment of Obesity and Type II Diabetes
10. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
11. Landauer, Inc. Sets Date And Time For Announcement Of Fiscal Fourth Quarter And Full Year 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015  Dr. Yair Walzer ... resolve vaginal health issues often caused by menopause. The MonaLisa ... no anesthesia, received FDA clearance in 2014. Dr. Walzer is ... to offer the special fractional CO 2 laser ... cancer survivors. In 2010 there were greater ...
(Date:5/29/2015)... DUBLIN , May 28, 2015 ... the addition of Jain PharmaBiotech,s new report ... to their offering. Drug delivery ... to other systems because of the anatomy and ... and nutrients to all organs of the body. ...
(Date:5/29/2015)... Massachusetts and SPARTANBURG, South Carolina ... The Guardian Research Network and Molecular Health have announced ... and molecular diagnostic decision support to the majority of ... Guardian Research Network will collaborate with Molecular Health to ... testing to identify cohorts from hundreds of thousands of ...
Breaking Medicine Technology:The Newest FDA-Cleared Breakthrough In Women's Health Treatments 2Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 2Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 3New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 2New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 3New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 4
... Complete Accrual in Fourth Quarter 2008, BERKELEY ... Board: GNTA) announced the presentation of a,progress update ... (oblimersen,sodium) Injection, the Company,s lead oncology product, in ... a satellite investigator,s,meeting held in conjunction with the ...
... a Year; Studies ... Milestone Payment to Micromet, BETHESDA, Md., and ZURICH, Switzerland, ... today announced the initiation of,formal preclinical safety studies for the ... for the achievement,of this milestone., Under a 2007 agreement ...
Cached Medicine Technology:Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma 2Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma 3Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma 4Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma 5Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases 2Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases 3Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases 4
(Date:5/29/2015)... Abington Hospital – Jefferson Health ... hospitals in the nation to join the ... and work toward achieving the Baby-Friendly USA© designation. ... on maternity care practices leading to Baby-Friendly designation. ... Prevention, EMPower is aimed at increasing breastfeeding rates ...
(Date:5/29/2015)... 29, 2015 According to a recent HealthDay ... full-time workers has a substance abuse problem - the data, ... 111,500 adults with full-time jobs, revealed that 9.5% of those ... year. (1) The National Council on Alcoholism and Drug Dependence ... and an estimated 70% of the 14.8 million illicit drug ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 To compile ... research, choosing systems that have several awards for clinical ... on what systems stood out to them in terms ... inclusion as well. , The 50 Great Health Systems ... Adventist Health System (Altamonte Springs, Fla.) , Advocate Health ...
(Date:5/29/2015)... New York, New York (PRWEB) May 29, 2015 ... and distributor of patented products, announces that it has ... Chat Room, a technology patent that aims to let ... various industry experts in real time. , "This is ... Expert Chat Room " said Scott J. Cooper, CEO ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Mediaplanet has ... to educate readers on the importance of proper sun ... within USA Today, with a circulation of approximately 250,000 ... digital component is distributed nationally, through a vast social ... sites and partner outlets. To explore the digital version ...
Breaking Medicine News(10 mins):Health News:Abington Hospital Selected to Join Baby-Friendly Hospital Initiative 2Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 2Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 3Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 4Health News:Becker's Hospital Review Names 50 Great Health Systems to Know 2Health News:Becker's Hospital Review Names 50 Great Health Systems to Know 3Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 3Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 4Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 5
... The Muscular Dystrophy Association today awarded 44 grants totaling ... of disease processes and to uncover new strategies for ... affecting more than a million Americans. The vital ... of the MDA Labor Day Telethon. "MDA-supported researchers ...
... DALLAS Feb. 8, 2011 The popular drug dutasteride ... in men who are at elevated risk of developing the ... researcher. In a study available in the January ... at an annual cost of $1,400, is impractical when compared ...
... one-half of U.S. adults who use the Internet participate ... not much is known about their quality and safety. ... networking websites targeting patients, researchers in the Children,s Hospital ... diabetes websites. Their audit found large variations ...
... University] Despite the intent of recent mental health ... reductions in co-pays for outpatient mental health care will ... seek that care, according to a new study by ... passed in 2008 and 2010, end an insurance industry ...
... quantities of data across different levels of detail, from ... of methods. Each method has its own type of ... across levels of detail and from different databases, for ... disease, is therefore challenging and time consuming. In addition, ...
... today in the European Heart Journal shows ... have long-term, serious health implications. Leading academics from ... heart attacks and cardiovascular disorders which often result in ... Warwick Medical School, explained: "If you sleep less ...
Cached Medicine News:Health News:MDA awards $13.5 million in grants for research treatments for neuromuscular diseases 2Health News:MDA awards $13.5 million in grants for research treatments for neuromuscular diseases 3Health News:MDA awards $13.5 million in grants for research treatments for neuromuscular diseases 4Health News:Dutasteride not a cost-effective way to prevent prostate cancer in some men 2Health News:Quality varies in social networking websites for diabetics 2Health News:Quality varies in social networking websites for diabetics 3Health News:Lower mental health co-pays do not help seniors seek care 2Health News:Major step taken toward an open and shared digital brain atlasing framework 2Health News:Late nights can lead to higher risk of strokes and heart attacks 2
... gives physicians, pharmacists, and ... clinical information to help ... decisions. Clinicians can trust ... because all information undergoes ...
... Derived from the trusted, ... database, this continually updated ... on thousands of commonly ... drugs and now includes ...
A handy, quick reference for physicians, nurses, and other health care providers treating cancer patients....
... updated for 2005, this practical handbook ... aspects of cancer chemotherapy. The book ... catalog of over 100 drugs both ... in cancer treatment. This new edition ...
Medicine Products: